Author(s):

Md. Abdur Rouf, Ananta Kumar Das, MST Mahfuza Khatoon, Nowshin Laila Mitu and Masum Shahriar

Abstract: Liver disease is among the most serious ailments and can be classified as acute or chronic hepatitis, hepatosis, and cirrhosis. Besides expensive and ineffectual modern therapeutic agents like steroids and chemotherapy, South East Asian countries like India and China have an edge in treating hepatic disorders employing their native botanicals. The present study was designed to evaluate the protective effects of Arogyavardhani on D-galactosamine (d-GalN)-induced fulminant hepatic failure. Rats were given an intraperitoneal injection of d-GalN (270 mg/kg). Arogyavardhani (10 mg/kg and 50 mg/kg) was administered orally for 14 days continuously, and on the last day at 1hour before the d-GalN injection. Rats were sacrificed 24 hours after the d-GalN. Silymarin (100 mg/kg body weight) was given orally as a standard hepatoprotective drug. The liver injury was assessed biochemically, investigating biochemical parameters like ALT, AST, ALP, Bilirubin, Total Protein, and Albumin. The survival rates after the application of Arogyavardhani at 24 h were also observed. D-galactosamine administration induced a significant increase (P≤0.01) in total bilirubin associated with a marked elevation in the activities of aspartate aminotransferase (AST), alanine aminotransferase (ALT), and alkaline phosphatase (ALP) as compared to control rats. The pretreatment of Arogyavardhani attenuated these changes in a dose-dependent manner. The survival rate of the OC groups was significantly higher than that of the d-GalN group. Our results suggest that Arogyavardhani has hepatoprotective effects against D-galactosamine induced hepatic damage. Therefore, Arogyavardhani may be used as a hepatoprotective agent against various liver diseases including toxic liver injury.

Pages: 12-19  |  1811 Views  865 Downloads

Download (657KB)